Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines

Auday Maki, Ramzi Mohammad, Syed Raza, Mohammad Saleh, Kanaka Durga Govindaraju, George Pettit, Ayad Al-Katib

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the antiproliferative agent dolastatin 10 on different grades of non-Hodgkin's lymphoma cell lines, All cell lines exposed to dolastatin 10 initiated an apoptosis process. Alteration of oncogenes and their product may direct the entry of the cells into apoptosis, among these oncogenes are bcl-2 and c-myc. All cell lines tested expressed c-myc and bcl-2 proteins. However, 24 h after exposing the cell lines to 1 ng/ml dolastatin 10, bcl-2 expression was abolished but there was no significant change in c-myc protein expression. The contradictory roles of c-myc in cell proliferation and death require that other gene(s) products regiment the outcomes of c-myc activity on a cell. A possible candidate for such a modifying gene is bcl-2, whose product prolongs cell survival and blocks apoptosis. Given the above, dolastatin 10 induction of cell arrest is the initiating signal to downregulate the anti-apoptotic bcl-2 and reactivate the apoptotic pathway. The reductions in bcl-2 may stabilize the c-myc proliferative action and induce apoptosis.

Original languageEnglish (US)
Pages (from-to)344-350
Number of pages7
JournalAnti-Cancer Drugs
Volume7
Issue number3
StatePublished - 1996
Externally publishedYes

Fingerprint

dolastatin 10
Non-Hodgkin's Lymphoma
Cell Line
Apoptosis
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-myc
bcl-2 Genes
Oncogene Proteins
Oncogenes
Antineoplastic Agents
Cell Survival
Cell Death
Down-Regulation
Cell Proliferation
Drug Therapy

Keywords

  • bcl-2
  • c-myc
  • Dolastatin 10
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Maki, A., Mohammad, R., Raza, S., Saleh, M., Govindaraju, K. D., Pettit, G., & Al-Katib, A. (1996). Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines. Anti-Cancer Drugs, 7(3), 344-350.

Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines. / Maki, Auday; Mohammad, Ramzi; Raza, Syed; Saleh, Mohammad; Govindaraju, Kanaka Durga; Pettit, George; Al-Katib, Ayad.

In: Anti-Cancer Drugs, Vol. 7, No. 3, 1996, p. 344-350.

Research output: Contribution to journalArticle

Maki, A, Mohammad, R, Raza, S, Saleh, M, Govindaraju, KD, Pettit, G & Al-Katib, A 1996, 'Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines', Anti-Cancer Drugs, vol. 7, no. 3, pp. 344-350.
Maki A, Mohammad R, Raza S, Saleh M, Govindaraju KD, Pettit G et al. Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines. Anti-Cancer Drugs. 1996;7(3):344-350.
Maki, Auday ; Mohammad, Ramzi ; Raza, Syed ; Saleh, Mohammad ; Govindaraju, Kanaka Durga ; Pettit, George ; Al-Katib, Ayad. / Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines. In: Anti-Cancer Drugs. 1996 ; Vol. 7, No. 3. pp. 344-350.
@article{2b4aae9852c0499f8113aec77b3b2b69,
title = "Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines",
abstract = "It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the antiproliferative agent dolastatin 10 on different grades of non-Hodgkin's lymphoma cell lines, All cell lines exposed to dolastatin 10 initiated an apoptosis process. Alteration of oncogenes and their product may direct the entry of the cells into apoptosis, among these oncogenes are bcl-2 and c-myc. All cell lines tested expressed c-myc and bcl-2 proteins. However, 24 h after exposing the cell lines to 1 ng/ml dolastatin 10, bcl-2 expression was abolished but there was no significant change in c-myc protein expression. The contradictory roles of c-myc in cell proliferation and death require that other gene(s) products regiment the outcomes of c-myc activity on a cell. A possible candidate for such a modifying gene is bcl-2, whose product prolongs cell survival and blocks apoptosis. Given the above, dolastatin 10 induction of cell arrest is the initiating signal to downregulate the anti-apoptotic bcl-2 and reactivate the apoptotic pathway. The reductions in bcl-2 may stabilize the c-myc proliferative action and induce apoptosis.",
keywords = "bcl-2, c-myc, Dolastatin 10, Non-Hodgkin's lymphoma",
author = "Auday Maki and Ramzi Mohammad and Syed Raza and Mohammad Saleh and Govindaraju, {Kanaka Durga} and George Pettit and Ayad Al-Katib",
year = "1996",
language = "English (US)",
volume = "7",
pages = "344--350",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines

AU - Maki, Auday

AU - Mohammad, Ramzi

AU - Raza, Syed

AU - Saleh, Mohammad

AU - Govindaraju, Kanaka Durga

AU - Pettit, George

AU - Al-Katib, Ayad

PY - 1996

Y1 - 1996

N2 - It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the antiproliferative agent dolastatin 10 on different grades of non-Hodgkin's lymphoma cell lines, All cell lines exposed to dolastatin 10 initiated an apoptosis process. Alteration of oncogenes and their product may direct the entry of the cells into apoptosis, among these oncogenes are bcl-2 and c-myc. All cell lines tested expressed c-myc and bcl-2 proteins. However, 24 h after exposing the cell lines to 1 ng/ml dolastatin 10, bcl-2 expression was abolished but there was no significant change in c-myc protein expression. The contradictory roles of c-myc in cell proliferation and death require that other gene(s) products regiment the outcomes of c-myc activity on a cell. A possible candidate for such a modifying gene is bcl-2, whose product prolongs cell survival and blocks apoptosis. Given the above, dolastatin 10 induction of cell arrest is the initiating signal to downregulate the anti-apoptotic bcl-2 and reactivate the apoptotic pathway. The reductions in bcl-2 may stabilize the c-myc proliferative action and induce apoptosis.

AB - It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the antiproliferative agent dolastatin 10 on different grades of non-Hodgkin's lymphoma cell lines, All cell lines exposed to dolastatin 10 initiated an apoptosis process. Alteration of oncogenes and their product may direct the entry of the cells into apoptosis, among these oncogenes are bcl-2 and c-myc. All cell lines tested expressed c-myc and bcl-2 proteins. However, 24 h after exposing the cell lines to 1 ng/ml dolastatin 10, bcl-2 expression was abolished but there was no significant change in c-myc protein expression. The contradictory roles of c-myc in cell proliferation and death require that other gene(s) products regiment the outcomes of c-myc activity on a cell. A possible candidate for such a modifying gene is bcl-2, whose product prolongs cell survival and blocks apoptosis. Given the above, dolastatin 10 induction of cell arrest is the initiating signal to downregulate the anti-apoptotic bcl-2 and reactivate the apoptotic pathway. The reductions in bcl-2 may stabilize the c-myc proliferative action and induce apoptosis.

KW - bcl-2

KW - c-myc

KW - Dolastatin 10

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0029942167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029942167&partnerID=8YFLogxK

M3 - Article

C2 - 8792010

AN - SCOPUS:0029942167

VL - 7

SP - 344

EP - 350

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -